[ad_1]
The new corona vaccine developed jointly by the US pharmaceutical company Pfizer and Germany’s BioNTech has a protective efficacy of more than 90%, and the World Health Organization (WHO) was also optimistic about it. By then, vaccination of dangerous groups can “fundamentally change” the global epidemic of the new crown.
The new corona vaccine developed jointly by Pfizer and BioNTech is in large-scale phase 3 clinical trials. Good news emerged yesterday as Pfizer announced that the protective efficacy of the vaccine exceeds 90%.
In this sense, the WHO was also optimistic. According to reports from Reuters and Associated Press, Bruce Aylward, senior adviser to the World Health Organization (WHO), told the WHO annual ministerial meeting yesterday that the results of the Pfizer vaccine trial were “very optimistic, although still much remains to be done, this is only a medium-term result, but the positive results that occurred yesterday will bring hope for the world to move forward.
Iward also noted that in March of next year, the United Nations agency hopes to begin vaccinating high-risk groups. The Pfizer vaccine can “fundamentally change the direction of this crisis.”
At present, the vaccine developed by Pfizer and BioNTech has not joined the Covid-19 Global Access Mechanism (COVAX) led by WHO. A total of 9 candidate vaccines around the world have joined COVAX, and the 9 vaccines will be distributed fairly around the world.
Pfizer and BioNTech have expressed their willingness to join COVAX, and the WHO has also expressed its consideration of including more vaccines.
In response to the good news from the Pfizer vaccine, WHO Secretary General Tedros Adhanom Ghebreyesus also tweeted that the news was “encouraging.”
According to global epidemic statistics from Johns Hopkins University in the United States, more than 50.81 million people have been diagnosed with a new coronary pneumonia and more than 1.26 million people have died.
(Zhongshi News Network)
[ad_2]
